December 30, 2004 - 9:08pm
From GlaxoSmithKline and Yamanouchi:
VESIcare® (solifenacin succinate) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence. In clinical studies, Vesicare 5 mg and 10 mg showed clinical and statistical improvements in all symptoms of OAB. Specifically, once-daily Vesicare was found to significantly reduce the number of incontinence episodes for patients during a 12-week study period.
Complete press release and prescribing information can be found at: http://www.vesicare.com/
FDA approval November 2004
Pill Identification - VESIcare (solifenacin succinate):
5 mg - Round, light yellow tablet debossed with Yamanouchi logo 150
10 mg - Round, light pink tablet debossed with Yamanouchi logo 151
For more information, please see the VESIcare website.
Updated 03-08-06
